Symposium - European Medical Journal

Continue

Symposiums

Hematology
8 Mins
23 Mar 2021

Is CD37-Targeted Therapy a Viable Alternative in the Treatment of Diffuse Large B-cell Lymphoma? Interviews with Two Key Opinion Leaders

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma and the most frequent non-Hodgkin lymphoma (NHL) in adults, accounting for 30–40%…
EMJ Dermatology 9 [Supplement 3] 2021 Feature Image
Dermatology
11 Mins
25 Feb 2021

Clinical Considerations Based On 5-Year Efficacy and Safety Data for the IL-23p19 Inhibitor Tildrakizumab

The indicative scaly, erythematous plaques of plaque psoriasis arise because of abnormal interactions between immune system cells and epidermal…
Rheumatology
10 Mins
19 Feb 2021

Diagnosis, Treatment Management, and the Genetic Basis of Psoriasis, Psoriatic Arthritis, and Spondyloarthritis

Psoriatic arthritis (PsA) is an inflammatory condition of the joints and the areas where tendons and ligaments connect with bone…
Oncology
3 Mins
19 Feb 2021

Final Results from the ClarIDHy Phase III Study of Ivosidenib Versus Placebo in Patients with Previously Treated Cholangiocarcinoma and an Isocitrate Dehydrogenase 1 (IDH1) Mutation

Cholangiocarcinoma (CCA) is a rare cancer for which there are limited effective therapies.1,2 Mutations in the isocitrate dehydrogenase 1 gene (IDH1)…
Dermatology
9 Mins
18 Feb 2021

Biological and Clinical Impacts of Ultraviolet-A on the Skin: New Insights

Terrestrial solar UVR consists of UVA (320–400 nm) and UVB (280–320 nm; typically around 295–320nm because of attenuation by the ozone…
Gastroenterology
10 Mins
11 Feb 2021

TDM and T2T – Perfect Partners?

This webinar opened with an introduction to therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) by Dr Baert, as well as an explanation…
Dermatology
11 Mins
10 Feb 2021

Long-term Efficacy and Safety of Tildrakizumab: 5-year Results from the reSURFACE 1 and 2 Phase III Trials in Patients with Moderate-to-severe Plaque Psoriasis

Psoriasis, a chronic systemic inflammatory disease with skin manifestations, can be an impediment to daily life. Accordingly…
Cardiology
4 Mins
29 Jan 2021

Mavacamten Positively Impacts Underlying Hypertrophic Cardiomyopathy Mechanisms as Well as Cardiac Structure and Function: Findings from the EXPLORER-HCM Study

Obstructive hypertrophic cardiomyopathy (HCM) is a progressive myocardial disorder characterised by dynamic left ventricular outflow tract (LVOT)…
We’ve noticed you’re accessing
from North/South America.